Talazoparib

Drug Profile

Talazoparib

Alternative Names: BMN-673; BMN-673ts; LT 006673; LT-00673; LT-673; MDV-3800; Talazoparib tosylate

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LEAD Therapeutics
  • Developer BioMarin Pharmaceutical; Medivation; National Cancer Institute (USA); St. Jude Childrens Research Hospital; University of California at San Francisco; University of Maryland Greenbaum Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Fluorobenzenes; Phthalazines; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia
  • Phase I Ewing's sarcoma; Pancreatic cancer; Small cell lung cancer
  • Preclinical Glioblastoma; Non-small cell lung cancer
  • Discontinued Haematological malignancies

Most Recent Events

  • 04 Jul 2017 Phase-II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03148795)
  • 03 Jun 2017 Efficacy and safety data from the phase II ABRAZO trial in Breast cancer released by Pfizer
  • 03 Jun 2017 Pfizer completes enrolment in its phase III EMBRACA trial for breast cancer in USA, Australia, Belgium, France, South Korea, Spain, Taiwan and the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top